Landos Biopharma, Inc. (LABP)
Chart Events
Performance Outlook
| Previous Close | 0.7176 |
| Open | 0.6961 |
| Bid | 0.6826 x 1300 |
| Ask | 0.6963 x 900 |
| Day's Range | 0.6786 - 0.7272 |
| 52 Week Range | 0.6060 - 16.1700 |
| Volume | |
| Avg. Volume | 98,355 |
| Market Cap | 27.534M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.0230 |
| Earnings Date | Jul 27, 2022 - Aug 01, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 20.46 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for LABP
Related Research
- Landos Biopharma, Inc.Daily – Vickers Top Insider Picks for 05/13/2022The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.RatingFair ValueEconomic Moat6 days agoArgus Research
- Zacks
The Zacks Analyst Blog Highlights Angion Biomedica, Applied Therapeutics, Bolt Biotherapeutics, Ikena Oncology, and Landos Biopharma
Angion Biomedica, Applied Therapeutics, Bolt Biotherapeutics, Ikena Oncology, and Landos Biopharma are part of Zacks top Analyst Blog
- GlobeNewswire
Landos Biopharma Reports First Quarter 2022 Results and Provides Business Update
On Track to Complete Review of Clinical Development Plans by Mid-2022 Top-Line Results for NX-13 Phase 1b and LABP-104 Phase 1 Trials Remain On Track for Mid-2022 Plans to Announce Timing of Phase 2b Trial of Omilancor Later this Year NEW YORK, May 12, 2022 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced financial results for the first quarter ended March
- Zacks
5 Biotech Stocks Set to Outpace Q1 Earnings Estimates
Let us take a look at some drug/biotech stocks, ANGN, APLT, BOLT, IKNA and LABP, which are poised to beat on first-quarter earnings.
